Methylene blue photodynamic therapy in malignant melanoma decreases expression of proliferating cell nuclear antigen and heparanases (2012)

Peer-Reviewed Study · Wagner M; Suarez ER; Theodoro TR; Machado Filho CDAS; Gama MFM; Tardivo JP; Paschoal FM; Pinhal MAS · February 2, 2012

Wagner M et al., 2012-02-02: Mouse study of methylene blue photodynamic therapy in malignant melanoma reporting a 99% fall in tumour volume and a 75% fall in tumour weight after two treatments compared with untreated mice, with expression of proliferating cell nuclear antigen down 75% and of both heparanase isoforms down 95%.

Two treatments with MB-PDT promoted a decrease of 99% decrease in tumour volume and 75% in tumour weight compared with untreated mice (P < 0.05).

Wagner M et al., 2012-02-02: Mouse study of methylene blue photodynamic therapy in malignant melanoma reporting a 99% fall in tumour volume and a 75% fall in tumour weight after two treatments compared with untreated mice, with expression of proliferating cell nuclear antigen down 75% and of both heparanase isoforms down 95%. Study type: animal (mouse melanoma model) with immunohistochemistry. N: mice, group sizes per full text. Country: Brazil (Universidade Federal de São Paulo; Faculdade de Medicina da Fundação ABC). Dose/light: methylene blue photodynamic therapy, two treatments; light parameters per full text. Comparator: untreated mice. Funder: 'Research Support, Non-U.S. Gov't'; specific funder not stated in record. Conflicts: not stated. Animal only – the same group's human melanoma experience is recorded separately. Study type: animal.